Sentences with phrase «major therapeutic target»

Currently, β - site APP - cleaving enzyme 1 (BACE1) is considered the major therapeutic target for Alzheimer's disease (AD)(Cole & Vassar, 2007; Vassar et al, 2014; Yan & Vassar, 2014; Barão et al, 2016).

Our results therefore suggest that arterial stiffness represents a major therapeutic target by which an otherwise intact physiological machinery may be exploited for blood pressure regulation.

«StimDust is the smallest deep - tissue stimulator that we are aware of that's capable of stimulating almost all of the major therapeutic targets in the peripheral nervous system,» said Rikky Muller, co-lead of the work and assistant professor of electrical engineering and computer sciences at Berkeley.

Objective: To study, at high spatial and temporal resolution, the conformational dynamics of the nicotinic receptors enabling neuronal communication in the brain, which are major therapeutic targets linked to cognition and tobacco dependence.

Not exact matches

«If they can develop a family of specific particles to target the major toxin families specifically, then this approach would have real value as a therapeutic.»

«The major known cancer driver genes are often mutated in the primary tumor and all metastases, and successfully targeting them in therapy could provide widespread therapeutic benefit,» said Townsend.

Altered sphingolipid levels in blood have been associated with depression and have been proposed as a therapeutic target for major depressive disorder.

«While the road to heparanase - targeting clinical drugs is long and fraught with risks, with this work we believe to have taken a major step in realising the therapeutic potential of this promising clinical target.»

The first quinquennium of technology translation at Sanger has seen significant expansion and maturation of the Sanger Institute's portfolio of spin out companies, establishment of the 50 FTE Centre for Therapeutic Target Validation and execution of licensing deals with major strategic benefits for the exploitation of key Institute assets.

Our group has 3 major goals: Develop novel therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma

â $ œWe have solved a major obstacle of using anti-miRNA as a therapeutic by being able to do a targeted delivery to only inflamed endothelial cells while all other tissues examined, including liver, lung, kidney, blood cells, spleen, etc showed no detectable side - effects, â $ Jo says.

«Our study demonstrates a new therapeutic approach to successfully target inflammation and fibrosis, representing a major advance in the field,» concluded Haldar.

ApoE as a major causative factor and therapeutic target in Alzheimer's disease and other neurodegenerative disorders; small - molecule structure correctors to convert apoE4 to apoE3 and reverse the detrimental effects of apoE4 on mitochondria and the cytoskeleton; small - molecule protease inhibitors to block the formation of toxic fragments of apoE4; Plasma lipoprotein metabolism regulation involving apoE and apoB; cholesterol homeostasis modulation by lipoprotein receptors controlling lipoprotein clearance by the liver; Plasma HDL cholesterol (HDL - C) metabolism in the progression of atherosclerosis; the genetic epidemiology of the metabolic syndrome and low HDL - C levels established by the Turkish Heart Study.